SAN DIEGO, CA--(Marketwire - Jul 26, 2012) - Cytori Therapeutics (
The dial-in information is as follows:
Dial-In Number: +1.866.791.6247
Passcode: 4549443
Prior to the webcast at approximately 4:05 PM Eastern Time on August 8, Cytori will issue its second quarter earnings release and post a quarterly shareholder letter to its Investor Relations homepage, which will review Cytori's second quarter performance.
The webcast will be available both live and by replay two hours after the call under "Webcasts" on the Company's Investor Relations website (http://ir.cytori.com).
About Cytori
Cytori Therapeutics is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. Our scientific data suggest ADRCs improve blood flow. As a result, we believe these cells can be applied across multiple "ischemic" conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori's proprietary technologies and products, including the Celution® System product family. www.cytori.com
Contact Information:
Contact:
Megan McCormick
mmccormick@cytori.com
+1.858.875.5279